Summary
Definição
História e exame físico
Principais fatores diagnósticos
- abnormal vaginal bleeding
- postcoital bleeding
- pelvic or back pain
- dyspareunia
- cervical mass
- cervical bleeding
Outros fatores diagnósticos
- mucoid or purulent vaginal discharge
- bladder, renal, or bowel obstruction
- bone pain
Fatores de risco
- human papillomavirus (HPV) infection
- age group
- HIV infection
- early onset of sexual activity (younger than 18)
- multiple sexual partners
- cigarette smoking
- immunosuppression
- history of STI
- oral contraceptive pill use
- high parity
- uncircumcised male partner
- micronutrient malnutrition
- low serum folate
- low vitamin C and E levels
- alcohol use
- low socioeconomic status
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- vaginal or speculum examination
- colposcopy
- biopsy
- human papillomavirus (HPV) testing
Investigações a serem consideradas
- CBC
- renal function testing
- liver function tests
- chest x-ray
- intravenous pyelogram
- renal ultrasound
- barium enema
- sigmoidoscopy
- cystoscopy
- MRI pelvis
- PET whole body
- PET/CT whole body
- CT of chest/abdomen/pelvis with intravenous/oral contrast
- molecular testing
Novos exames
- p16 and Ki67 biomarker expression
Algoritmo de tratamento
nonpregnant stage IA1 without LVSI: desiring fertility
nonpregnant stage IA1 without LVSI: not desiring fertility
nonpregnant, stage IA1 with LVSI: desiring fertility
nonpregnant, stage IA1 with LVSI: not desiring fertility
nonpregnant stage IA2: desiring fertility
nonpregnant stage IA2: not desiring fertility
nonpregnant stage IB1: desiring fertility
nonpregnant stage IB1: not desiring fertility
nonpregnant stage IB2: desiring fertility
nonpregnant, stage IB2: not desiring fertility
nonpregnant stage IIA1
nonpregnant stage IB3 or IIA2
nonpregnant stage IIB to IVA
nonpregnant, stage IVB (metastatic disease)
nonpregnant local or regional recurrent disease
pregnant
Colaboradores
Autores
Richard T. Penson, MD, MRCP

Clinical Director
Medical Gynecologic Oncology
Division of Hematology Oncology
Massachusetts General Hospital
Boston
MA
Declarações
RTP reports serving on scientific advisory boards for AstraZeneca, Eisai, GSK Inc., ImmunoGen Inc., Merck & Co., Mersana, Novocure, Roche Pharma, Sutro Biopharma, Vascular Biogenics Ltd; data and safety monitoring boards for AstraZeneca and Roche Pharma; institutional research funding (as Principal Investigator) for Array BioPharma Inc., AstraZeneca, Eisai Inc., Genentech Inc., Regeneron, Sanofi-Aventis US LLC, Tesaro Inc., Vascular Biogenics Ltd; and royalties from BMJ Publishing, UptoDate, Elsevier Ltd, Wolters Kluwer Health, and Wiley-Blackwell.
Andrea L. Russo, MD
Director
Gynecologic Radiation Oncology
Associate Clinical Director
Department of Radiation Oncology
Massachusetts General Hospital
Boston
MA
Declarações
ALR declares that she has no competing interests.
Agradecimentos
Dr Richard T. Penson and Dr Andrea L. Russo would like to gratefully acknowledge Dr Larissa J. Lee, their co-contributor who is sadly deceased, and to acknowledge Dr Neil S. Horowitz and Dr Anthony H. Russell, previous contributors to this topic.
Declarações
NSH and AHR declare that they have no competing interests.
Revisores
Tracilyn Hall, MD
Assistant Professor of Gynecologic Oncology
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine Houston
Houston
TX
Declarações
TH declares that she has no competing interests.
Linda Yang, MD
Fellow
Minimally Invasive Gynecologic Surgery
Magee Women's Hospital
University of Pittsburgh Medical Center
PA
利益声明
LY declares that she has no competing interests.
Deirdre Lyons, MB, BCh, BAO, MRCOG
Consultant in Obstetrics & Gynaecology
Lead Clinician in Colposcopy
Imperial College Healthcare NHS Trust
London
UK
利益声明
DL declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
参考文献
关键文献
Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv72-83.全文 摘要
Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.全文 摘要
Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.全文 摘要
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].全文
参考文献
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
鉴别诊断
- Human papillomavirus (HPV) infection
- Pelvic infection
- Nabothian cyst
更多 鉴别诊断指南
- Screening for cervical cancer
- Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV
更多 指南患者教育信息
Cervical cancer
HPV (human papillomavirus) vaccine
更多 患者教育信息შედით სისტემაში ან გამოიწერეთ BMJ Best Practice
ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას